Patent · US Active

Use of low doses of oligonucleotides antisense to TGF-β genes in the treatment of brain tumors

US8097597B2 · kind B2 · utility

2Cited by

0References

9Claims

0Family size

Assignee

Antisense Pharma GmbH · DE

Inventors

Karl-Hermann Schlingensiepen · Bovenden, DE
Reimar Schlingensiepen · Regensburg, DE

Key dates

Filing date	May 4, 2006
Grant date	Jan 17, 2012
Priority date	—
Expiry date	Mar 21, 2027

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention is related to the use of at least one oligonucleotide with a length of from about 8 to about 30 nucleotide building blocks for manufacturing a pharmaceutical preparation for the prophylaxis and/or the treatment of diseases, that are modulated by TGF-beta2, TGF-beta1, TGF-beta3, VEGF, interleukin-10, c-jun, c-fos, and/or prostaglandin E2 in a mammal, wherein said oligonucleotide hybridizes with a messenger RNA of a TGF-beta2, TGF-beta1, TGF-beta3, VEGF, interleukin-10, c-jun, c-fos and/or prostaglandin E2 gene and wherein said preparation comprises said oligonucleotide in a concentration of about 1 microM to about 25 microM.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.